The CEO of global pharmaceutical and services company Clinigen Group sat down with In Vivo to discuss the growing, and often advantageous, incorporation of unlicensed medicines into drug development companies’ commercialization strategies. Go behind the facts and figures to understand the implications of this increasingly common practice, which presents significant advantages – and some very real challenges – to the companies employing it. Dive into the complexities of using unlicensed medicines in commercialization strategies with this revealing article from In Vivo.
Strategy At Novartis: Culture Change As The 'How' Behind The 'What'
- Newsletter
- 6 Pages
- Global
